Skip to main content

Table 1 Patient characteristics

From: Thoracic skeletal muscle quantification: low muscle mass is related with worse prognosis in idiopathic pulmonary fibrosis patients

Variable

Total

Men

Women

P-value

Number of patients, n

180

143 (79.4%)

37 (20.6%)

 

Age, years

69.1 (44–94)

68.7 (44–89)

70.0 (52–94)

0.214

Height, meters, m

1.6 ± 0.1 (1.4–1.8)

1.7 ± 0.1 (1.5–1.8)

1.5 ± 0.1 (1.4–1.7)

<  0.001

Weight, kg

63.9 ± 10.3 (33.1–97.3)

65.7 ± 10.2 (33.1–97.3)

56.9 ± 7.1 (46.0–73.0)

<  0.001

BMI, kg/m2

23.9 ± 3.2 (12.2–34.9)

23.8 ± 3.3 (12.2–34.9)

24.0 ± 3.2 (17.6–29.6)

0.794

Ever smoker, %

129 (71.6%)

126 (88.1%)

3 (8.1%)

<  0.001

Smoking history, pack-years

31.0 ± 23.3 (0–150)

31.5 ± 23.3 (0–150)

8.3 ± 7.6 (0–15)

0.088

Diabetes, n

59 (32.8%)

47 (32.9%)

12 (32.4%)

1.000

Use of Statins or Sulfonylureas or Glinides, n

66 (36.7%)

52 (37.1%)

13 (35.1%)

1.000

FVC, L

2.6 ± 0.8 (0.9–4.8)

2.8 ± 0.8 (0.9–4.8)

1.8 ± 0.5 (0.9–2.8)

<  0.001

FVC, % predicted

76.3 ± 17.1 (31–110)

77.1 ± 17.1 (31–110)

72.8 ± 16.6 (34–106)

0.185

FEV1, L

2.1 ± 0.6 (0.8–3.9)

2.2 ± 0.6 (0.8–3.9)

1.3 ± 0.4 (0.8–2.3)

<  0.001

FEV1, % predicted

89.0 ± 18.6 (34–128)

89.3 ± 18.9 (34–128)

88.2 ± 17.7 (45–119)

0.753

FEV1/FVC, %

81.44 ± 8.97 (31–100)

80.53 ± 9.07 (31–100)

85.15 ± 7.60 (70–98)

0.007

TLC, L

4.73 ± 1.42 (1.91–8.40)

5.03 ± 1.31 (2.55–8.40)

3.10 ± 0.70 (1.91–4.70)

<  0.001

DLCO, ml/min/mm Hg

12.2 ± 5.2 (2.9–46.5)

12.8 ± 5.3 (2.9–46.5)

9.9 ± 3.7 (4.2–17.3)

0.005

DLCO, % predicted

69.6 ± 23.1 (20–149)

71.6 ± 23.3 (20–149)

61.1 ± 20.6 (25–102)

0.025

T4 level muscle CSA, cm2

96.0 ± 25.6 (36.8–163.5)

102.4 ± 23.4 (36.8–163.5)

71.4 ± 18.1 (33.4–111.3)

<  0.001

aT4 level muscle index, cm2/m2

35.7 ± 8.5 (13.2–55.9)

37.2 ± 8.2 (13.2–55.9)

30.0 ± 7.5 (17.9–45.0)

<  0.001

T12 Erector spinae muscle CSA, cm2

28.2 ± 9.1 (9.8–55.9)

29.4 ± 8.2 (13.2–55.9)

23.5 ± 7.5 (9.8–38.8)

0.001

bT12 muscle index, cm2/m2

10.5 ± 3.3 (3.8–23.2)

10.7 ± 3.3 (3.8–23.2)

9.9 ± 3.1 (4.5–15.8)

0.184

Follow-up time, months

37.9 ± 22.5 (0.1–91)

37.0 ± 21.9 (0.1–90.8)

41.3 ± 25.0 (0.4–91)

0.301

GAP Index score

3.3 ± 1.4 (0–7)

3.5 ± 1.4 (1–7)

2.8 ± 1.5 (0–6)

0.006

1-year survival, number, (%)

157 (87.2%)

124 (86.7%)

33 (89.2%)

0.688

2-year survival, number, (%)

138 (76.7%)

107 (74.8%)

31 (83.8%)

0.284

  1. Continuous variables are presented as mean ± standard deviation (range) and categorical variables are presented as numbers (percentage)
  2. Abbreviations: BMI Body Mass Index, FEV1 Forced Expiratory Volume, FVC Forced Vital Capacity, TLC Total Lung Capacity, DLCO diffusing capacity of carbon monoxide, CSA Cross Sectional Area, GAP gender, age, and physiologic variables
  3. aT4 level muscle index = CSA of pectoralis, intercostalis, paraspinals, serratus, and latissimus muscles at T4 level/height2
  4. bT12 level muscle index = CSA of erector spinae muscle at T12 level/height2
Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us